Rapid communication: Inhibition of adenosine deaminase by azapurine ribonucleosides

[1]  R. Wolfenden,et al.  Transition-state stabilization by adenosine deaminase: 1,6-addition of water to purine ribonucleoside, the enzyme's affinity for 6-hydroxy-1,6-dihydropurine ribonucleoside, and the effective concentration of substrate water at the active site. , 1989, Biochemistry.

[2]  J. Brisson,et al.  X-Ray and1H NMR Analyses of the Structure and Conformation of 2-Azacoformycin, a Potent Inhibitor of Adenosine Deaminase. , 1986 .

[3]  J. Chern,et al.  Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine. , 1986, Cancer research.

[4]  J. Brisson,et al.  Correction. X--ray and (1)H NMR Analyses of the Structure and Conformation of 2-Azacoformycin, a Potent Inhibitor or Adenosine Deaminase. , 1985, Journal of the American Chemical Society.

[5]  R. Parks,et al.  Transport of deoxycoformycin in human erythrocytes. Measurement by adenosine deaminase titration and radioisotope assays. , 1984, Biochemical pharmacology.

[6]  H. Showalter,et al.  Adenosine deaminase inhibitors. Synthesis and biological evaluation of (+/-)-3,6,7,8-tetrahydro-3-[(2-hydroxyethoxy)methyl]imidazo[4,5-d] [1,3]diazepin-8-ol and some selected C-5 homologues of pentostatin. , 1983, Journal of medicinal chemistry.

[7]  B. Mitchell,et al.  Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy. , 1983, Cancer research.

[8]  Carl Frieden,et al.  Adenosine deaminase: solvent isotope and pH effects on the binding of transition-state and ground-state analogue inhibitors. , 1983, Biochemistry.

[9]  J. Hutton,et al.  The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy , 1981 .

[10]  E. Gelfand,et al.  Biochemistry of diseases of immunodevelopment. , 1981, Annual review of biochemistry.

[11]  T. Spector,et al.  Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. , 1977, Biochemical pharmacology.

[12]  W. Valentine,et al.  Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. , 1977, Science.

[13]  A. Albert.  Covalent Hydration in Nitrogen Heterocycles , 1976 .

[14]  S. Cha,et al.  Tight-binding inhibitors-II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin. , 1975, Biochemical pharmacology.

[15]  S. Cha,et al.  Tight-binding inhibitors-I. Kinetic behavior. , 1975, Biochemical pharmacology.

[16]  R. Buckley,et al.  Molecular form of adenosine deaminase in severe combined immunodeficiency. , 1974, Biochemical and biophysical research communications.

[17]  A. Albert,et al.  V-triazolo(4,5-d)pyrimidines (8-azapurines). XI. Preparation of 2-benzyl-V-triazolo (4,5-d)pyrimidine (8-benzyl-8-azapurine). , 1972, Journal of the Chemical Society. Perkin transactions 1.

[18]  B. E. Evans,et al.  [A potential transition state analog for adenosine deaminase]. , 1970, Journal of the American Chemical Society.

[19]  D. D. Perrin,et al.  3H-1,2,3,4,6-penta-azaindenes (“8-azapurines”). Part II. Rates and equilibria for reversible water addition , 1966 .

[20]  A. Albert.  3H-1,2,3,4,6-penta-azaindenes (“8-azapurines.”) Part I. Covalent hydration, syntheses, and reductions , 1966 .